Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT02023073
Recruiting Observational

Determination of Physical Parameters Relevant to Ophthalmic Lasers

NCT02023073 · tracked via the Priya Life Science Israel tracker
Sponsor
Sheba Medical Center
Phase
Observational
Started
2018-07-01
Last updated
2025-10-06

Condition(s) studied

Healthy Volunteers

Study summary

The use of lasers in medicine in general, and diagnosis and treatment in ophthalmology in particular, increased significantly. Making retinal surgery using lasers have become increasingly common. The goal: to diagnose eye diseases safely

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18-40 years * Refraction up to ±0.25D, * General good health * Written informed consent to participate in the study. Exclusion Criteria: * known current ophthalmic pathology * known past ophthalmic pathology (including LASIK surgery) * eye glasses or contact lenses

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Goldschleger Eye Research Institute, Sheba Medical Center, Tel Litwinsky Israel Recruiting

More Sheba Medical Center trials in Israel

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer Recruiting
Clemastine Treatment in Individuals With Williams Syndrome Active, not recruiting
Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury Recruiting
Hepatopulmonary Radio-sterilization With Immunotherapy Starting soon
ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study Enrolling by invitation

Other trials for the same condition

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers Recruiting
General Pre-Trial Screening Protocol for Infectious Diseases Research Recruiting
Pilot Clinical Trial of Ultrasound Guided Aortic Compression for Arresting Abdominal Aortic Blood Flow in Healthy Volunteers. This Isn't Device Feasibility, But Rather the Feasibility of a Clinical Maneuver; Specifically, Evaluating Whether the Technique Can Achieve the Anticipated Out Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02023073 on ClinicalTrials.gov ↗ ← All trials in Israel